and the bronze medal goes to...?

BIOTECH	3 Month Movement
RHT	492.31%
ADO	138.81%
MLA	129.73%
MDG	128.57%
OBJ	111.76%
PVA	104.44%
IMI	100.00%
PGL	92.31%
SUD	82.86%
BXN	66.67%
LFC	66.67%
NSP	63.27%
UNS	59.46%
ELX	51.79%
PME	49.56%
PAB	44.67%
GBI	44.44%
IPD	43.75%
BLT	41.38%
SBN	37.50%
ICS	35.29%
PRR	35.14%
TIS	31.82%
GXL	30.46%
ALT	25.00%
SDI	24.11%
AVH	23.81%
AHZ	23.08%
OSL	20.83%
VHL	18.18%
AZV	17.78%
CLV	16.33%
PAA	15.38%
SRX	15.10%
FPH	14.86%
LHC	13.50%
RHC	13.04%
DVL	12.50%
QRX	12.33%
ACW	10.00%
PYC	9.09%
AGX	8.33%
GID	6.49%
ONT	5.63%
ACL	5.26%
SOM	4.62%
CUV	4.39%
SIP	4.39%
PXS	4.00%
NAN	3.53%
SHL	3.38%
CSL	3.32%
PBP	2.50%
LCT	2.38%
LBT	1.27%
PRY	0.81%
ANN	0.16%
BPO	0.00%
PHG	0.00%
PLD	0.00%
PNO	0.00%
SFP	0.00%
SIE	0.00%
TDX	0.00%
VLA	0.00%
VRT	0.95%
COH	1.33%
CZD	1.33%
BIT	2.25%
EBO	3.01%
IDT	3.23%
VEI	3.62%
MVP	4.17%
OSP	4.29%
MYX	4.55%
NEU	4.76%
RMD	5.98%
ACG	6.25%
BNO	6.49%
VSC	6.54%
AVX	7.14%
GTG	7.93%
CMP	8.24%
ANO	8.33%
BPH	8.33%
API	8.46%
CAJ	8.51%
GLH	8.89%
IDT	9.09%
MSB	9.26%
AJJ	10.00%
AMT	10.00%
IIL	10.00%
UBI	10.71%
SPL	11.11%
POH	11.54%
OIL	11.67%
AIY	12.12%
CIR	12.24%
ACR	12.45%
CYC	13.79%
NLS	14.29%
KKT	15.09%
CDY	15.79%
PGC	15.91%
IVX	16.00%
ANP	16.67%
CGS	17.98%
CTG	19.40%
UCM	19.44%
RVA	19.64%
MWR	20.00%
NRT	22.00%
IMU	22.73%
IMC	25.00%
BNE	28.00%
CYP	28.33%
MGZ	28.95%
BRC	31.58%
ISN	49.21%

492.31%

MktCap: $27,796,335
Cash in Bank: $745,000
Q4/2013 Cash Burn: $198,000

Resonance Health Limited is an Australian healthcare company specializing in development and commercialization of magnetic resonance imaging related technology for diagnosis and management of human disease. The Company has representatives in Australia, the UK, Germany and the USA and a distributor in Turkey, the UAE, Saudi Arabia and Egypt. RHT's lead product is FerriScan, a non-invasive test for liver iron concentration.

in the news...

Resonance Health received FDA 510(k) market clearance for the HepaFat-Scan medical device. HepaFat-Scan is a software technology that can be used to accurately measure the amount of fat in the liver, using MRI medical images. This is a significant milestone for the Company. Gaining FDA approval enables Resonance Health to commercially market the test in the United States, providing patients and clinicians with an offering that provides key differences to other diagnostic tests for fatty liver. HepaFat-Scan provides considerable improvements over other diagnostic tools for fatty liver disease. The superior sensitivity of HepaFat-Scan will provide patients and doctors with a more accurate diagnostic tool as part of a structured intervention protocol or clinical research trial. HepaFat-Scan will be attractive not only to patient and health care professions but also to the pharmaceutical industry developing new therapies to address fatty liver disease.
In obtaining FDA approval, Resonance Health demonstrated the accuracy and reproducibility of HepaFat-Scan through a combination of bench testing and clinical studies.

announcement links...

14/11/2013: Alliance Medical Limited Contract
14/11/2013: AGM 2013-Presentation to Shareholders
02/12/2013: Response to ASX Price and Volume Query
20/12/2013: FDA Clearance for HepaFat-Scan
07/01/2014: Response to ASX Price and Volume Query

barcharts technical 0pinion...

138.81%

MktCap: $130,296,255
Cash in Bank: $7,476,000
Q4/2013 Cash Burn: $915,000

Anteo Diagnostics is a surface coating company with a proprietary family of enabling chemistries, called Mix&Go. Mix&Go enables the fast and easy production of superior surfaces for the biotechnology, diagnostics and pharmaceutical industries. The Mix&Go family of protein binding chemistries is gaining traction with a wide spectrum of clients in the in vitro diagnostics industry including bead manufacturers, test developers, test manufacturers, and life science companies.

in the news...

A five-phase project has been agreed with BBI. The first two phases are planned to be largely undertaken by Anteo scientists in Brisbane and the remainder in Cardiff in close consultation with Anteo scientists. The initial two phases are now nearing completion, on time, and the results are very positive. Several shipments have been dispatched to Cardiff for verification of our findings in their hands. Progress is such that the frequency of teleconferences between the technical collaborators has increased significantly. We are very pleased with the data we have been able to provide and, in general, with the spirit of the collaboration.

announcement links...

08/11/2013: Anteo and BBI Solutions Sign Heads of Terms
13/11/2013: Boardroom Radio Interview with Dr Geoff Cumming
16/12/2013: Anteo completes a $5.5 million placement
17/12/2013: Boardroom Radio Interview $5.5 Million Placement
30/01/2014: Quarterly Activities Report Appendix 4C

barcharts technical 0pinion...

129.73%

MktCap: $43,375,182
Cash in Bank: $2,829,000
Q4/2013 Cash Burn: $691,000

Medical Australia Limited is a medical company engaged in the manufacture, distribution and sale of medical devices used by healthcare facilities and critical care services in global market. MLA focuses on three core clinical therapy areas namely medication delivery (intravenous (IV) systems); reuse prevention; and surgical and anaesthesia products. MLA has two key businesses, TUTA and Clements, with operations in Australia, New Zealand, Asia and United Kingdom.

in the news...

During the quarter, MLA achieved a significant milestone by completing the acquisition of regenerative animal stem cell company, MediVet Pty Ltd. MLA now holds a 60.5% interest in MediVet America LLC, and 100% of MediVet Pty Ltd which encompasses Canada, USA, Great Britain, Continental Europe, the Middle East, Australia and the Asia Pacific Region. The integration of MLA and MediVet is well advanced, and the Company looks forward to updating Shareholders on the full financial and operational impact of this integration in the coming weeks. Pre-merger, MLA and MediVet have been collaborating on a number of new products for both the human and animal healthcare markets. MLA has made significant progress in this regard with a pipeline of new projects and supply contracts to be announced over the coming months. This has added considerable strength to MLA’s product base, and will bring additional revenue streams from customers in domestic and international markets.

announcement links...

10/12/2013: MLA Raises $4 Million To Fast Track Growth
16/01/2014: Response to ASX Price Query Letter
31/01/2014: Appendix 4C
31/01/2014: Quarterly Report December 2013

barcharts technical 0pinion...

128.57%

MktCap: $8,019,845
Cash in Bank: $1,793,000
Q4/2013 Cash Flow Positive: $1,468,000

Medtech Global Limited is an Australia-based company engaged in the development and sale by way of sub-license of healthcare technologies worldwide. The Company provides software solutions and licensing to healthcare professionals, hospitals and individuals in Australia, New Zealand and USA. MDG also has 51.6% interest in ConSova Corporation, a limited liability company incorporated in Denver, State of Colorado, which is involved in the healthcare cost containment business.

Link to MedTech Global Products
Link to ConSova Corp

announcement links...

26/11/2013: Half Yearly Report & Accounts
22/01/2014: Appendix 4C - quarterly
23/01/2014: Comment relating to Appendix 4C

barcharts technical 0pinion...

111.76%

MktCap: $51,587,685
Cash in Bank: $5,049,000
Q4/2013 Cash Burn: $206,000

OBJ Limited develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare, and consumer goods sectors. OBJ’s proprietary magnetic fields and magnetic micro-arrays provide a low cost, powerful and chemistry-free method of enhancing drug delivery and product performance, and the company's technology platforms are now at the fore front of new product developments across a number of main-stream commercial sectors with a number of the world’s leading companies.

in the news...

The following transcript is from a 2013 AGM Presentation delivered by OBJ's Technical Director - a rare insight compared to the conservative approach taken by the board with market announcement over the years whilst nurturing relationships with some of the largest companies in the world

"We have completed the first of 3 clinical studies and in fact the most important of those with P&G. Before you ask, no I can’t tell you what the outcomes of those are because the clinical results are not OBJ’s property, however the outcomes are being sufficiently engaging for them that we are now moving - that we have now moved forward into negotiations regarding possible product development for the first application of OBJ’s technologies across P&G’s product range. I hope to be able to expand on that in coming announcements shortly... Something that we learnt I suppose, last year as we were allowed deeper and deeper into these multi-billion dollar companies, we really did realize that OBJ’s technical strength was actually quite significantly superior to their own and these are the biggest companies in the world. We are now being asked to support those development programs because we can offer a speed of results and a capability that’s beyond the vast majority of our partners... again keeping in mind that all of our partner activities are fully funded, they put up the cheques. The days of us investing in partner activities are gone - they're paying the bills and that really changes the economics, dynamics... So in a nutshell, that’s what we have done with your company during 2013, it’s been a terribly exciting period and I think there is some very near term stuff that I think you will be very happy with, and that we will be very very keen to announce as soon as we possibly can.

announcement links...

28/11/2013: Patent Portfolio Update
28/11/2013: 2013 AGM Presentation
12/12/2013: First BodyGuard Trial Success
13/12/2013: Appointment of Licensing Specialist
16/12/2013: GSK Pharma progresses to Second Phase

barcharts technical 0pinion...

www.barchart.com

Holding Disclosure:
AHZ
OBJ